Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-10-09 17:40 |
VIVALIS ANNOUNCED THE FIRST EVER MARKETING AUTHORIZATION FOR A VACCINE PRODUCED…
|
English | 364.9 KB | ||
| 2012-10-09 17:40 |
VIVALIS ANNONCE LA PREMIERE AUTORISATION DE MISE SUR LE MARCHE D'UN VACCIN PROD…
|
French | 305.2 KB | ||
| 2012-10-05 18:00 |
VIVALIS : ACTIONS ET DROITS DE VOTE SEPTEMBRE 2012
|
English | 134.3 KB | ||
| 2012-09-14 07:00 |
VIVALIS ANNONCE L'ENTREE EN PHASE III DU VACCIN GRIPPE PRODUIT SUR LA LIGNEE CE…
|
French | 311.9 KB | ||
| 2012-09-14 07:00 |
VIVALIS ANNOUNCES THE PHASE III ADVANCEMENT OF THE EB66® CELL BASED HUMAN INFLU…
|
English | 443.8 KB | ||
| 2012-09-07 17:45 |
VIVALIS : ACTIONS ET DROIT DE VOTE AOUT 2012
|
English | 133.6 KB | ||
| 2012-09-04 17:40 |
VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH COLLABORATION
|
English | 399.8 KB | ||
| 2012-09-04 17:40 |
VIVALIS ANNONCE LA SIGNATURE D'UN NOUVEL ACCORD DE RECHERCHE POUR UNE NOUVELLE …
|
French | 221.0 KB | ||
| 2012-08-31 10:33 |
VIVALIS RAPPORT SEMESTRIEL
|
French | 392.9 KB | ||
| 2012-08-30 19:07 |
VIVALIS : RAPPORT SEMESTRIEL
|
English | 392.9 KB | ||
| 2012-08-30 17:40 |
VIVALIS PUBLIE SES RÉSULTATS DU PREMIER SEMESTRE
|
French | 311.8 KB | ||
| 2012-08-30 17:40 |
VIVALIS PUBLISHES ITS FIRST HALF RESULTS
|
English | 302.0 KB | ||
| 2012-08-28 17:40 |
VIVALIS ANNONCE LA SIGNATURE D'UNE NOUVELLE LICENCE DE RECHERCHE AVEC BIOFACTURA
|
French | 234.8 KB | ||
| 2012-08-28 17:40 |
VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE AGREEMENT WITH BIOFACT…
|
English | 410.2 KB | ||
| 2012-08-21 17:40 |
Successful growth of BioDiem's Virus in VIVALIS EB66® Cell Line
|
English | 197.8 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
